Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands			3 Months Ended
	Nov. 24, 2021	Jun. 09, 2020	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill			$ 115,414	$ 117,516
Goodwill			(2,102)
Fair value of contingent consideration		$ 230,000
Property and equipment, net			17,215	$ 16,955
Adamas Pharmaceuticals
Business Acquisition [Line Items]
Cash and cash equivalents	$ 90,064
Accounts receivable	11,156
Inventories	20,200
Prepaid expenses and other current assets	5,077
Property and equipment	1,254
Intangibles	450,100
Other assets	(1,620)		$ (1,600)
Deferred income tax liabilities	3,722
Other assets	4,822
Total fair value of assets acquired	582,673
Accounts payable	(4,592)
Accrued expenses and other current liabilities	(8,014)
Current debt	(138,315)
Operating lease liabilities, long-term	(5,224)
Deferred income tax liabilities	(52,866)
Total fair value of liabilities assumed	(209,011)
Total identifiable net assets	2,102
Total identifiable net assets	373,662
Goodwill	37,451
Goodwill	(2,102)
Total purchase price	411,113
Cash consideration paid	400,806
Fair value of contingent consideration	10,307
Total purchase price	411,113
Adamas Pharmaceuticals | As Initially Reported
Business Acquisition [Line Items]
Cash and cash equivalents	90,064
Accounts receivable	11,156
Inventories	20,200
Prepaid expenses and other current assets	5,077
Property and equipment	1,254
Intangibles	450,100
Other assets	6,442
Total fair value of assets acquired	584,293
Accounts payable	(4,592)
Accrued expenses and other current liabilities	(8,014)
Current debt	(138,315)
Operating lease liabilities, long-term	(5,224)
Deferred income tax liabilities	(56,588)
Total fair value of liabilities assumed	(212,733)
Total identifiable net assets	371,560
Goodwill	39,553
Total purchase price	411,113
Cash consideration paid	400,806
Fair value of contingent consideration	10,307
Total purchase price	$ 411,113